阿德福韦酯胶囊联合大黄蟅虫胶囊治疗肝纤维化疗效观察

Effect of adefovir dipivoxil capsules combined with Dahuang Zhechong capsules in the treatment of hepatic fibrosis

目的：进一步研究肝纤维化治疗中阿德福韦酯胶囊联合大黄蟅虫胶囊的临床治疗效果。方法收集2010年1～12月来我院进行肝纤维化治疗的62例患者临床资料进行详细研究，将上述患者随机分为两组，31例对照组患者接受阿德福韦酯治疗，31例治疗组患者在对照组治疗基础上，接受大黄蟅虫胶囊治疗。在入院第2天以及治疗结束后,抽取患者空腹静脉血进行肝功能检测与肝纤维化指标检测。结果治疗前两组患者总胆红素水平、丙氨酸转氨酶、谷草转氨酶、白蛋白、球蛋白水平、血清肝纤维化指标相比，差异无统计学意义（P＞0.05）；治疗后，两组患者总胆红素水平、丙氨酸转氨酶、谷草转氨酶水平、血清肝纤维化指标显著下降，治疗组与对照组相比，差异具有统计学意义（P＜0.05）。结论肝纤维化治疗中阿德福韦酯胶囊联合大黄蟅虫胶囊的临床治疗效果显著，有效提高纤维化治疗效果，改善患者肝功能状态，安全、有效，值得进一步推广。

Objective To study the efficacy of adefovir dipivoxil capsules combined with Dahuang Zhechong capsules in the treatment of hepatic fibrosis. Methods During January 2010 to December 2010, 62 cases of patients with liver fibrosis were selected, they were randomly divided into two groups： the treatment group and the control group, each group of 31 cases, the control groups were given adefovir dipivoxil capsules treatment, the treatment group were given Adefovir dipivoxil capsules combined with Dahuang Zhechong capsules treatment. On the second day of admission and after treatment, respectively taken fasting in patients with venous blood, tested for liver function and liver fibrosis markers. Results Two groups of total bilirubin level, alanine aminotransferase, aspartate aminotransferase, albumin, globulin level, serum liver fibrosis index before treatment had no statistically significant difference（P 〉 0.05）; Two groups of total bilirubin level, alanine aminotransferase, aspartate aminotransferase, serum liver fibrosis index significantly decreased after treatment, the difference between the two groups was statistically significant（P〈0.05）. Conclusion The effect of adefovir dipivoxil capsules combined with Dahuang Zhechong capsules in the treatment of hepatic fibrosis was remarkable, it can effectively improve the efficacy of hepatic fibrosis, improve patients liver function, and worthy of further promotion.